Radiopharm Theranostics Ltd has released a press release.
New RAD202 data confirms positive tumor uptake
Filed with ASX ·
6ix hasn’t read this filing yet.
Radiopharm Theranostics Limited on 6ix
Earlier from Radiopharm Theranostics
- Half Year Report and Appendix 4D 31 December 2024
- Clinical trial data shows RAD 101 detects Brain Metastases
- Lantheus increases shareholding in RAD with A$8m placement
- Strategic Co-Development Partnership with Lantheus for Aus
- RAD 202 receives approval to start Phase 1 therapeutic trial
Later from Radiopharm Theranostics
- First patient dosed in Phase IIb imaging for Brain Mets
- Radiopharm Theranostics Doses First Patient with 18F-RAD101 in U.S. Phase 2b Imaging Study of Brain Metastasis
- Radiopharm Theranostics to Participate in the D. Boral Capital Inaugural Global Conference
- Acceleration of RAD204 Phase 1 dose escalation trial
- Radiopharm Theranostics Accelerates 177Lu-RAD204 Phase 1 Dose Escalation Clinical Trial Based on Positive Recommendation from Data Safety and Monitoring Committee (DSMC)
Follow Radiopharm Theranostics into a list and get an email when it puts out news.
Follow Radiopharm Theranostics